EUVC E552 | EUVC Summit 2025 | Nirmesh Patel, Amino Collective: Future of Medicine: How VC is Driving Healthcare Innovation
At the EUVC Summit 2025, Nirmesh Patel from Amino Collective took the stage with a message that felt less like a pitch and more like a call to arms. His focus? The intersection of AI, health, and bio—and why Europe is uniquely positioned to lead this next era.
We’re still waiting for the first blockbuster drug developed using large AI models. But don’t mistake that for inaction. As Nirmesh put it:
“It’s fundamentally changed how everyone does research in this space.”
So much so that the Nobel Prize committee had no choice but to take notice.
That shift is already reshaping how scientists think, experiment, and build companies—and it’s opening the door for a new generation of outlier founders at the earliest stages.
Amino Collective invests pre-seed and seed into health and bio, and Nirmesh was unequivocal:
“Europe has all the ingredients required to make the next healthcare giants.”
Here’s what he sees:
Technical founders now thinking commercially from Day 1.
Citizens more willing to contribute data to studies, even if they don’t cancel that January gym membership.
Stable grant funding across Europe—especially in contrast to recent volatility at U.S. institutions like the NIH.
On-continent innovation in manufacturing mRNA at scale—key to pandemic preparedness.
These aren’t future predictions. They’re current capabilities, and they’re maturing fast.
Venture is about betting on outliers.
In AI x Bio, the next outliers are likely being formed right now.
“We’re at the very early stages of the collision between AI, health, and bio. The companies that will define the future are just starting.”
If you want to back the next transformative firm in medicine, don’t just look to the coasts.
Look to Europe. The science is here. The funding is here. The talent is ready.
“I truly believe the future of medicine is European.”
So do we.
AI Has Already Transformed Research. The Market Impact Comes Next.Why Europe? The Ingredients Are Already Here.From Outliers to Giants